1887

Chapter 22 : Quinolones in Pediatrics

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Quinolones in Pediatrics, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap22-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap22-2.gif

Abstract:

Quinolones are bactericidal and active against a wide range of gram-positive and gram-negative bacterial pathogens relevant to pediatric infections. These include , nosocomially acquired , methicillin-sensitive and methicillin-resistant and . Widespread use of fluoroquinolones has resulted in emergence of resistance; therefore, it is important to give careful thought to the site of infection and pathogens in each patient. Use of fluoroquinolones in children should be strictly limited to the specific infections complicated by special conditions for which the benefit of these drugs is clear and for which no alternative safe and effective antibiotic therapy is available. Quinolones penetrate well into tissues, especially into infected tissues, and are accumulated within macrophages and the polymorphonuclear leukocytes. Photosensitivity occurs most often with agents containing a halogen substituent at the 8 position, such as lomefloxacin, clinafloxacin, and sparfloxacin. Experience with the use of quinolones in children has increased, particularly in children with cystic fibrosis who are given ciprofloxacin. Antibiotic therapy has been shown to be a major factor in improving survival in patients with cystic fibrosis. Gastrointestinal infections are a major health problem in infants and children worldwide, causing severe morbidity and mortality. Ciprofloxacin has been shown to be an effective agent in the treatment of osteomyelitis, especially when the pathogen is a gram-negative organism. In neonates, besides gram-negative organisms, pathogens such as , group B streptococci, and are also susceptible to gatifloxacin, moxifloxacin, and clinafloxacin.

Citation: Ghaffar F, McCracken, Jr. G. 2003. Quinolones in Pediatrics, p 343-354. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch22
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817817.chap22
1. Acar, J. F.,, and F. W. Goldstein. 1997 Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24: S67 S73.
2. Acar J. F.,, T. F. O'Brien,, F. W. Goldstein,, and R. N. Jones. 1993. The epidemiology of bacterial resistance to quinolones. Drugs 45( Suppl. 3): S24 S28.
3. Adam D. Use of quinolones in pediatric patients. 1989. Rev. Infect. Dis. 11( Suppl. 5): S1113 S1116.
4. Alghasham, A. A.,, and M. C. Nahata. 2000. Clinical use of fluoroquinolones in children. Ann. Pharmacother. 34: 347 359.
5. Amacher, D. E.,, S. J. Schomaker,, T. D. Gootz,, and P. R. McGuirk. 1989. Proteoglycan and procollagen synthesis in rat embryo limb bud cultures treated with quinolone antibacterials. Altern. Methods Toxicol. 7: 307 312.
6. Ambrose, P. G.,, R. C. Owens,, R. Quintiliani,, and C. H. Nightingale. 1997. New generations of quinolones: with particular attention to levofloxacin. Conn. Med. 61: 269 272.
7. Anco, M.,, G. Bossi,, D. Gaselli,, G. Cosi,, A. Villa,, and G. Beluffi. 1995. Long term magnetic resonance survey of cartilage damage in leukemic children treated with fluoroquinolones. Pediatr. Infect. Dis. J. 14: 713 714.
8. Aradottir, E.,, and R. Yogev. 1999. The use of fluoroquinolones in pediatrics: a reassessment. Semin. Pediatr. Infect. Dis. 10: 31 37.
9. Arguedas, A.,, L. Sher,, E. Lopez,, X. Saez-Llorens,, K. Skuba,, and P. Pierce. 2001. Gatifloxacin treatment of recurrent/nonresponsive acute otitis media, abstr. G-1534. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Avila-Aguero, M.,, J. Blumer,, J. Bradley,, X. Saex-Llorens,, M. O'Ryan,, D. Grasela,, F. Lacreta,, M. Swingle,, G. H. McCracken,, and H. Jafri. 2001. Single dose safety and pharmacokinetics of intravenous gatifloxacin in pediatric patients, abstr. A-39. In Program and Abstr 41st Intersci Conf Antimicrob. Agents Chemother. American Society for Microbiology, Washington, D.C.
11. Ball, P. 1989. Long term use of quinolones and their safety. Rev. Infect. Dis. 11: S1365 S1370.
12. Bannon, M. J.,, P. R. Stutchfield,, A. M. Weindling, and Damjanovic. 1989. Ciprofloxacin in neonatal Enterobacter cloacae septicemia. Arch. Dis. Child. 64: 1388 1391.
13. Bast, D. J.,, D. E. Low,, C. L. Duncan,, L. Kilburn,, L. A. Mandell,, R. J. Davidson,, J. C. S. De Azavedo. 2000. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob. Agents Chemother. 44: 3049 3054.
14. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40: 639 651.
15. Bedu, A.,, I. Naar,, and C. Faraoux. 1998. Hypertension intracraienne chez un nouveau-ne traite par quinolones. Presse Med. 27: 1140 1142.
16. Bhattacharya, S. K.,, M. K. Bhattacharya,, P. Dutta,, D. Sen,, R. Raisaily,, A. Moitra,, and S. C. Pal. 1991. Randomized clinical trial of norfloxacin for shigellosis. Am. J. Trop. Med. Hyg. 45: 683 687.
17. Bhutta, Z. A. 1997. Quinolone-resistant Salmonella paratyphi B meningitis in newborn: a case report. J. Infect. 35: 308 310.
18. M. D. Blum,, D. J. Graham,, and C. A. McCloskey. 1994. Temafloxacin syndrome: review of 95 cases. Clin. Infect. Dis. 18: 946 950.
19. Borcherding, S. M.,, R. Stevens,, R. A. Nicholas,, C. R. Corley,, and T. Self. 1996. Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions. J. Fam. Pract. 42: 69 78.
20. Bosso, J. A. 1989. Use of ciprofloxacin in cystic fibrosis patients. Am. J. Med. 87( Suppl. 5A): 120S 127S.
21. Bow, E. J., , E. Rayner,, and T. J. Louie. 1988. Comparison of norfloxacin with co-trimoxazole for infection prophylaxis in acute leukemia: the trade-off for reduced gram-negative sepsis. Am. J. Med. 84: 847 854.
22. Burkhardt, J. E.,, J. N. Walterspiel,, and U. B. Schhad. 1997. Quinolone arthropathy in animals versus children. Clin. Infect. Dis. 25: 1196 1204.
23. Campo, P.,, A. Gutierrez,, and C. Landron de Guevera. 1997. Evolution of susceptibility of non-typhi Salmonella in a Spanish hospital (1992-1994) and report of a Salmonella ser. Typhimurium isolate resistant to quinolones. Eur. J. Epidemiol. 13: 239 241.
24. Capparelli, E.,, F. Lecreta,, J. Blumer,, J. Bradley,, T. Wells,, G. Kearns,, M. Swingle,, G. Duncan,, and D. Graela. 2000. Single dose safety and pharmacokinetics of oral gatifloxacin in pediatric patients, abstr. A-15. In Program and Abstr 40th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, D.C.
25. Carratala, J.,, A. Fernandez-Sevilla,, F. Tubau,, M. Callis,, and F. Gudiol. 1995. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin. Infect. Dis. 20: 557 560.
26. Chen, D. K.,, A. McGeer,, J. C. de Azavedo,, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341: 233 239.
27. Chen, S.,, R. Abels,, J. Blumer,, A. Chow,, H. Goldstein,, G. Kearns,, S. Maldonado,, G. Noel,, T. Wells,, and S. Spielberg. 2001. Single-dose pharmacokinetics and tolerability of intravenous levofloxacin in pediatric patients, abstr. A-42. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society of Microbiology, Washington, D.C.
28. Church, D. A.,, J. F. Kanga,, R. J. Kuhn,, T. T. Rubio,, W. A. Spohn,, J. C. Stevens,, P. G. Painter,, B. E. Thurberg,, D. C. Haverstock,, R. Y. Perroncel,, and R. M. Echols. 1997. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr. Infect. Dis. J. 16: 97 105.
29. Chysky, V.,, K. Kapila,, R. Hullmann,, G. Arcieri,, P. Schacht,, and R. Echols. 1991. Safety of ciprofloxacin in children. World-wide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 19: 289 296.
30. Cruciani, M.,, E. Concia,, A. Nevarra,, L. Pervers,, F. Bonetti,, M. Arico,, and L. Nespoli. 1989. Prophylactic co-trimoxazole vs norfloxacin in neutropenic children-perspective randomized study. Infection 17: 65 69.
31. Cuevas, L. E.,, P. Kazembe,, G. K. Mughogho,, G. S. Tillotson,, and C. A. Hart. 1995. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J. Infect. Dis. 171: 728 731.
32. Dagan, R.,, L. Piglansky,, D. Greenberg,, A. Leiberman,, P. Pierce,, L. Wilhelm,, and E. Libovitz. 2001. Dynamics of nasopharyngeal pneumococcal carriage in children with recurrent and non-responsive acute otitis media treated with gatifloxacin, abstr. G-1825. In Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
33. Dagan, R.,, F. Schlaeffer,, and M. Einhorn. 1989. Parenteral fluoroquinolones for the treatment of children with lifethreatening infections. Infection 18: 237 238.
34. Drlica, K.,, and X. L. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbial. Rev. 61: 377 392.
35. Daiichi Pharmaceutical. Product information. February 1998. Floxacin otic (ofloxacin otic solution). Fort Lee, N.J.
36. Dutta, P.,, U. Mitra,, R. Rasaily,, M. R. Saha,, B. Manna,, M. K. Chatterjee,, T. Garai,, M. Sengupta,, and S. K. Bhattacharya. 1997. Multi-drug resistant typhoid fever with diarrhea. Indian Pediatr. 34: 891 899.
37. Elting, L. S.,, G. P. Bodey,, and B. H. Keefe. 1992. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin. Infect. Dis. 14: 1201 1207.
38. Ericsson, C. D.,, P. C. Johnson,, H. L. Dupont,, D. Morgan,, J. A. M. Bitsura,, and F. J. Cabada. 1987. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travellers' diarrhea: a placebo-controlled, randomized trial. Ann. Intern. Med. 106: 216 220.
39. Ferguson, J.,, and R. Dawe. 1997. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. J. Antimicrob. Chemother. 40( Suppl. A): 93 98.
40. Force R. W.,, M. C. Hart,, S. A. Plummer,, D. A. Powell,, and M. C. Nahata. 1995. Topical ciprofloxacin for otorrhoea after tympanostomy tube placement. Arch. Otolaryngol. Head Neck Surg. 121: 880 884.
41. Forster, C.,, R. Schwabe,, E. Lozo,, U. Zippel,, J. Vormann,, T. Gunther,, H. J. Merker,, and R. Stahlmann. 1997. Quinoloneinduced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in the target tissues and pharmacokinetics. Arch. Toxicol. 72: 26 32.
42. Freifeld, A.,, and P. Pizzo. 1997. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr. Infect. Dis. J. 16: 140 146.
43. Fuji, R.,, H. Meguro,, O. Arimasu,, K. Ushijima,, T. Abe,, S. Nakazawa,, H. Sato,, A. Narita,, K. Niino,, and H. Ichihashi. 1990. Evaluation of norfloxacin in the pediatric field Pediatric Study Group for Norfloxacin. Jpn. J. Antibiot. 43: 181 215.
44. Gendrel, D.,, and F. Moulin. 2001. Fluoroquinolones in paediatrics. Drugs. 3: 365 377.
45. Goepp, J. G.,, C. K. Lee,, T. Anderson,, J. D. Dick,, J. M. Stokoe,, and J. Eiden. 1992. Use of ciprofloxacin in an infant with ventriculitis. J. Pediatr. 121: 303 305.
46. Goldbarb, J.,, R. C. Stern,, M. D. Reed,, T. S. Yamashita,, C. M. Myers,, and J. L. Blumer. 1987. Ciprofloxacin monotherapy for acute pulmonary exacerbation of cystic fibrosis. Am. J. Med. 82( Suppl. 4A): 174 179.
47. Gough, A. W.,, O. B. Kasali,, R. E. Sigler,, and V. Baragi. 1992. Quinolones arthropathy-acute toxicity to immature articular cartilage. Toxicol. Pathol. 20: 436 449.
48. Green, S. D. R. 1996. Management of typhoid fever and multi-resistant salmonellosis in children. Presented at First European Congress of Chemotherapy, Glasgow.
49. Green, S. D. R.,, S. M. Ilunga,, J. S. Cheesburgh,, G. S. Tillotson,, M. Hitchens,, and D. Felmingham. 1993. The treatment of neonatal meningitis due to gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the CSF. J. Infect. 26: 253 256.
50. Green, S. D. R.,, and F. Mewa Ilunga. 1992. An open study of ciprofloxacin for the treatment of proven or suspected extraintestinal salmonellosis in African children: a preliminary report. Adv. Antimicrob. Antineoplast. Chemother. 11: 181 187.
51. Guyon, P.,, A. M. Cassel-Beraud,, G. Rakotonirine,, and D. Gendrel. 1994. Short-term pefloxacin therapy in Madagascan children with shigellosis due to multiresistant organisms. Clin. Infect. Dis. 19: 1172 1173.
52. Hawkey, P. M. 2000. Resistance to ciprofloxacin and the new quinolones. J. Chemother. 12: 12 14.
53. Hendershot, E. F. 1995. Fluoroquinolones. Infect. Dis. Clin. N. Am. 3: 715 730.
54. Hoban, D. J., , R. N. Jones,, L. J. Harrell,, M. Knudson,, and D. Sewell. 1993. The North American component (the United States and Canada) of an international comparative MIC trial monitoring ofloxacin resistance. Diagn. Microbiol. Infect. Dis. 17: 157 161.
55. Hoge, C. W.,, L. Bodhidatta,, and C. Tungaem. 1995. Emergence of nalidixic acid resistant Shigella dysenteriae type 1 in dessert. Int. J. Epidemiol. 24: 1228 1232.
56. Hooper, D. C. 1998. Bacterial topoisomerases, anti-topoisomerases, and antitopoisomerase resistance. Clin. Infect. Dis. 27( Suppl. 1): S54 S63.
57. Hooper, D. C., 1995. Quinolones, p. 364 376. In G. L. Mandell,, J. E. Benett,, and R. Dolin (ed.). Principles and Practice of Pediatric Infectious Diseases, 4th ed. Churchill Livingstone, New York, N.Y.
58. Houwen, R. H.,, C. M. Bijleveld,, and H. G. Vries- Hospers. 1987. Ciprofloxacin for cholangitis after hepatic portoenterostomy. Lancet. i: 1367 111;
59. Iqbal, J.,, M. Rahman,, and M. S. Kabir. 1999. Ciprofloxacin resistance among community-derived methicillin-resistant Staphylococcus aureus (MRSA) strains. Southeast Asian J. Trop. Med. Public Health. 30: 779 780.
60. Ingham, B.,, D. W. Brentuall,, E. A. Dale,, and V. A. McFadzean. 1977. Arthropathy induced by antibacterial fused N-alkyl-pyridone-3-carboxylic acid. Toxicol. Lett. 1: 21 26.
61. Isaacs, D.,, M. P. E. Slack,, A. R. Wilkinson,, and A. W. Westwood. 1986. Successful treatment of pseudomonas ventriculitis with ciprofloxacin. J. Antimicrob Chemother. 17: 535 538.
62. Jahan, Y.,, and A. Hossain. 1997. Multiple drug-resistant Shigella dysenteriae type 1 in Rajban district. Bangladesh. J. Diarrhoeal Dis. Res. 15: 17 20.
63. Ji, B.,, N. Lounis,, C. Maslo,, C. Truffot-Pernot,, P. Bonnafous,, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis . Antimicrob. Agents Chemother. 42: 2066 2069.
64. Reference deleted.
65. Kato, M.,, S. Takada,, Y. Kashida,, and M. Nomura. 1995. Histologic examination on Achilles tendon lesions induced by quinolone antibacterial agents in juvenile rats. Toxicol. Pathol. 23: 385 392.
66. Kubin, R. 1993. Safety and efficacy of ciprofloxacin in paediatric patients: review. Infection 21: 413 421.
67. Lang, R.,, S. Goshen,, and A. Raas-Rothschild. 1992. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children. Pediatr. Infect. Dis. J. 11: 925 929.
68. Leibovitz, E.,, J. Janco,, L. Piglansky,, J. Press,, P. Yagupsky,, H. Reinhart,, I. Yaniv,, and R. Dagan. 2000. Oral ciprofloxacin vs IM ceftriaxone as empiric treatment of acute invasive diarrhea in children. Pediatr. Infect. Dis. ]. 19: 1060 1067.
69. Leigh, D. A.,, B. Walsh,, K. Harris,, P. Hankok,, and G. Travers. Pharmacokinetics of ofloxacin and the effect of the fecal flora of healthy volunteers. J. Antimicrob. Chemother. 22( Suppl. C): l15 125.
70. Linseman, D. A.,, L. A. Hampton,, and D. G. Branstetter. 1995. Quinolone-induced arthropathy in neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin. Fundam. Appl. Toxicol. 28: 59 64.
71. Lolekha, S. S.,, P. Vivulbanhitkit,, and P. Poonyarit. 1991. Response to antomicrobial therapy for shigellosis in Thailand. Rev. Infect. Dis. 13( Suppl. 4): 342 346.
72. Lumbiganon, P.,, K. Pengsaa,, and T. Sookpranee. 1991. Ciprofloxacin in neonates and its possible adverse effects on the teeth. Pediatr. Infect. Dis. J. 10: 619 620.
73. Lumpkin, M. M. June 9 1999. Public health advisory. Trovan (trovafloxacin/ alatrofloxacin mesylate). U.S. Food and Drug Administration, Washington, D.C. http://www.fda.gov/cder/news/trovan/trovan-advisory.htm. Accessed March 22, 2000.
74. Lutsar, L.,, I. R. Friedland,, L. Wubbel,, C. C. McCoig,, H. S. Jafri,, W. Ng,, F. Ghaffar,, and G. H. McCracken. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalsporin-resistant pneumococcal meningitis. 1998. Antimicrob. Agents Chemother. 42: 2650 2655.
75. Makhani, S.,, K. R. Postlethwaite,, N. M. Renny,, C. J. Kerawala,, and A. T. Carton. 1998. Atypical cervico-facial mycobacterial infections in childhood. Br. J. Oral Maxillofac. Surg. 36: 119 122.
76. Martinez-Martinez, L.,, A. Pascual,, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351: 797 799.
77. Ma run, S. J.,, J. M. Meyer,, S. J. Chuck,, R. Jung,, C. R. Messick,, and S. L. Pendland. 1998. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann. Pharmacother. 32: 320 326.
78. Meunier, F.,, S. H. Zinner,, H. Gaya,, T. Calandra,, C. Viscoli,, J. Klastersky,, and M. Glauser. 1991. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob. Agents Chemother. 35: 873 878.
79. Morrison, G. A.,, and C. M. Baiy. 1988. Relapsing malignant otitis externa successfully treated with ciprofloxacin. J. Laryngol. Otol. 102: 872 876.
80. Murphy, G. S., Jr.,, P. Echeverria,, L. R. Jackson,, M. K. Arness,, C. LeBron,, and C. Pitarangsi. 1996. Ciprofloxacinand azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin. Infect. Dis. 22: 868 869.
81. Naber, K. G. 2001. Which fluoroquinolones are suitable for the treatment of urinary tract infections?. Int. J. Antimicrob. Agents. 17: 331 341.
82. Okusu, H.,, D. Ma,, and H. Nikaido. 1996. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178: 306 308.
83. Ostergaard, C.,, T. K. Sorensen,, J. D. Knudsen,, and N. Frimodt-Moller. 1998. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob. Agents Chemother. 42: 1706 1712.
84. Paris, M. M.,, S. M. Hickey,, M. Trujillo,, S. Shelton,, and G. H. McCracken, Jr. 1995. Evaluation of CP-99, 219, a new fluoroquinolone, for treatment of experimental penicillinand cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 39: 1243 1246.
85. Patrick, C. C. 1997. Use of fluoroquinolones as prophylactic agents in patients with neutropenia. Pediatr. Infect. Dis. J. 16: 135 139.
86. Pecquet, S.,, S. Ravoire,, and A. Andremont. 1990. Fecal excretion of ciprofloxacin after a single oral dose and its effect on fecal bacteria in healthy volunteers. J. Antimicrob. Chemother. 26: 145 150.
87. Peltola, H.,, M. Vaarala,, O. V. Renkonen,, and P. J. Neuvonen. 1992. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob. Agents Chemother. 36: 1086 1090.
88. Pertuiset, E.,, G. Lenoir,, M. Jehanne,, F. Douchain,, M. Guillot,, and C. J. Menkes. 1989. Tolerance articulaire de la pefloxacine et de 1 ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev. Rhum. Mai. Osteoartic. 56: 735 740.
89. Piccirillo, J. F.,, and S. M. Parnes. 1989. Ciprofloxacin for the treatment of chronic ear disease. Laryngoscope 99: 510 513.
90. Pigaru, C.,, R. Bartolome,, B. Almirante,, A. M. Planes,, J. Gavalda,, and A. Pahissa. 1997. Bacteremia due to Campylobacter species: clinical findings and antimicrobial susceptibility patterns. Clin. Infect. Dis. 25: 1414 1420.
91. Poole, K.,, K. Tetro,, Q. Zhao,, S. Neshat,, D. E. Heinrichs,, and N. Bianco. 1996. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob. Agents Chemother. 40: 2021 2028.
92. Rattan, A. 1999. Mechanisms of resistance to fluoroquinolones. Natl. Med. J. India. 12: 162 164.
93. Raz, R.,, and D. Miron. 1994. Oral ciprofloxacin for treatment of infection following nail puncture wounds of the foot. Clin. Infect. Dis. 21: 194 195.
94. Richard, D. A.,, S. Nousia-Arvanitakis,, V. Sollich,, B. J. Hampel,, B. Sommerauer,, and U. B. Schaad. 1997. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging. Pediatr. Infect. Dis. J. 16: 572 578.
95. Robson, R. A. 1992. Quinolone pharmacokinetics. Int. J. Antimicrob. Agents 2: 3 10.
96. Rowe, B.,, L. R. Ward,, and E. J. Threlfall. 1997. Multidrug resistant Salmonella typhi: a worldwide epidemic. Clin. Infect. Dis. 24( Suppl. 1): S106 S109.
97. Rubio, T. T.,, M. V. Miles,, J. T. Lettieri,, R. J. Kuhn,, R. M. Echols,, and D. A. Church. 1997. Pharmacokinetic disposition of sequential intra venous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr. Infect. Dis.]. 16: 112 117.
98. Saez-Llorens, X.,, C. McCoig,, J. M. Feris,, S. L. Vargas,, K. P. Klugman,, G. D. Hussey,, R. W. Frenk,, L. H. Falleiros-Carvalho,, A. G. Arguedas,, J. Bradley,, A. C. Arrieta,, E. R. Wald,, S. Pancorbo, G. H. McCracken, Jr., and the Trovan Meningitis Study Group. 2002. Quinolone treatment for pediatric bacterial meningitis. A comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr. Infect. Dis. J. 21: 14 22.
99. Saito, H.,, M. Gidoh,, and K. Kobayashi. 1998. In vitro activity of gatifloxacin (AM-1155) against Mycobacterium leprae, abstr. E-185. In Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemother. American Society for Microbiology, Washington, D.C.
100. Schaad, U. B.,, E. Sander,, J. Wedgwood,, and T. Schaffner. 1992. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr. Infect. Dis. J. 11: 1047 1049.
101. Schaad, U. B.,, C. Stoupis,, J. Wedgwood,, H. Tschaeppeler,, and P. Vock. 1991. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pedatr. Infect. Dis. J. 10: 723 729.
102. Stahlberg, H. J.,, K. Goehler,, and M. GuUlaume. 1998. Pharmacokinetics of the R- and S-enantiomers of gatifloxacin (GTX), a new fluoroquinolone antibiotic, following single oral doses to healthy Caucasian volunteers, abstr. A- 25. In Programs and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
103. Stahlmann, R.,, H. J. Merker,, N. Hinz,, I. Chahoud,, J. Webb,, W. Herger,, and D. Neubert. 1990. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch. Toxicol. 64: 193 204.
104. Stein, G. E. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23( Suppl. 1): S19 S24.
105. Taylor, D. N.,, J. L. Sanchez,, W. Candler,, S. Thornton,, C. McQueen,, and P. Echeverria. 1991. Treatment of travellers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone: a placebo controlled, randomized trial. Ann. Intern. Med. 114: 731 734.
106. Thomassen, M. J.,, C. A. Demko,, and C. F. Doershuk. 1987. Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr. Pulmonol. 3: 334 351.
107. Van Wijk, A. E.,, T. P. V. M. Dejong,, and J. D. Van Gool. 1992. Using quinolones in urinary tract infections in children. Antimicrob. Agents Chemother. 11: 157S 161S.
108. Vila, J.,, J. Ruiz,, P. Goni,, and T. Jimenez de Anta. 1997. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii . J Antimicrob. Chemother. 39: 757 762.
109. Waites, K. B.,, K. C. Canupp,, and G. E. Kenny. 1998. Quantitative determination of in vitro susceptibilities of Mycoplasma hominis to fluoroquinolones and quinopristin354 dalfopristin, using E-tests and commercially prepared media, abstr. E-31. In Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
110. Wolfson, J. S.,, and D. C. Hooper. 1989. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev. Infect. Dis. 11: S960 S968.
111. Yee, C. L.,, C. Duffy,, P. G. Gerbino,, S. Stryker,, and G. J. Noel. 2002. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr. Infect. Dis. J. 21: 525 529.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error